The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NeoOPTIMIZE: Phase II trial of adaptive switching of neoadjuvant FOLFIRINOX (FFX) to gemcitabine/nab-paclitaxel (GA) resectable/borderline resectable (BR)/locally advanced (LA) pancreatic adenocarcinoma (PDAC).
 
Lyndsey Sandow
No Relationships to Disclose
 
Justin Grenet
No Relationships to Disclose
 
Adel Kardosh
Consulting or Advisory Role - AstraZeneca; Eisai; Genentech
Research Funding - Natera
 
Emerson Chen
Consulting or Advisory Role - MDoutlook
Research Funding - G1 Therapeutics (Inst); Ipsen Bioscience Inc. (Inst); Jazz Pharmaceuticals (Inst); Merck Sharp & Dohme Llc (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca
Other Relationship - Horizon CME
 
Guillaume Pegna
Consulting or Advisory Role - Ipsen
 
Skye Mayo
No Relationships to Disclose
 
Robert Eil
No Relationships to Disclose
 
Patrick Worth
No Relationships to Disclose
 
Flavio Rocha
Consulting or Advisory Role - AstraZeneca; Histosonics; Medtronic; Oncosil
Travel, Accommodations, Expenses - Lynx Group
 
Nima Nabavizadeh
Consulting or Advisory Role - GRAIL
 
Aaron Grossberg
Consulting or Advisory Role - Endevica Bio
 
Alexander Guimaraes
Honoraria - Agfa Healthcare
Consulting or Advisory Role - BioClinica; Calyx; Merck; Takeda
Expert Testimony - Witherspoon Kelly
 
Bryan Foster
No Relationships to Disclose
 
Shaun Goodyear
Consulting or Advisory Role - PDX Pharmacy
 
Erin Taber
No Relationships to Disclose
 
Dove Keith
No Relationships to Disclose
 
Gordon Mills
Stock and Other Ownership Interests - Bluedot; Catena; ImmunoMET; Nuvectis Pharma; SignalChem; Tarveda Therapeutics; Turbine
Honoraria - Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog Bio; Lilly; MedaCorp; NanoString Technologies; Nuvectis Pharma; PDX Pharmacy; Qureator; Roche; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Consulting or Advisory Role - Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog Bio; Lilly; MedaCorp; NanoString Technologies; Nuvectis Pharma; PDX Pharmacy; Qureator; Roche; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation; Genentech; GlaxoSmithKline; ImmunoMET; Komipharm; Lilly; NanoString Technologies; Ovarian Cancer Research Foundation; Prospect Creek Foundation
Patents, Royalties, Other Intellectual Property - DSP technology patent with Nanostring; HRD assay to Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca; Chrysalis Biomedical Advisors; ImmunoMET; Michigan Primary Care Consortium; Pfizer; Symphogen
 
Rosalie Sears
Consulting or Advisory Role - Larkspur; Novartis; Rappta Therapeutics
Research Funding - Cardiff Oncology (Inst)
Travel, Accommodations, Expenses - Rappta Therapeutics
 
Brett Sheppard
No Relationships to Disclose
 
Charles Lopez
Consulting or Advisory Role - Ipsen
Research Funding - Roche/Genentech (Inst); Servier (Inst); Taiho Pharmaceutical (Inst)